IQVIA Holdings | Independent Board Chairman at IQVIA Holdings

Status
Filed
AGM date
Previous AGM date
Proposal number
5
Resolution details
Company ticker
IQV
Lead filer
John Chevedden
Resolution ask
Adopt or amend a policy
ESG theme
  • Governance
ESG sub-theme
  • Independent board
Type of vote
Shareholder proposal
Filer type
Shareholder
Company sector
Health Care
Company HQ country
United States
Resolved clause
Shareholders request that the Board of Directors adopt an enduring policy, and amend the governing documents as necessary in order that 2 separate people hold the office of the Chairman and the office of the CEO as soon as possible.
Supporting statement
The Chairman of the Board shall be an Independent Director. A Lead Director shall not be a substitute for an independent Board Chairman. The Board shall have the discretion to select an interim Chairman of the Board, who is not an Independent Director, to serve while the Board is required to seek an Independent Chairman of the Board on an accelerated basis. This policy could be phased in when there is a contract renewal for our current CEO or for the next CEO transition although it is better to adopt it now. An independent Board Chairman at all times improves corporate governance by bringing impartiality, objective oversight, and external expertise to board decisions, mitigating conflicts of interest, enhancing transparency, and boosting shareholder confidence. This detached perspective allows the chairman to focus on shareholder interests, strengthen management accountability, and provide critical checks and balances, ultimately contributing to long-term sustainability and credibility. This may be a particularly good time to consider the merits of this proposal. IQVIA stock was at $285 in 2021 and fell to $206 in late 2025 despite a robust stock market. Unfavorable news reports and developments regarding IQVIA emerged in 2025. Financial analyses from July 2025 noted that IQVIA’s year-over-year net income had declined, indicating pressure on profitability margins. Reports in July and September 2025 pointed to IQVIA’s high debt level as a key risk factor. By the second quarter, long-term debt had increased, and the company had a liabilities-to-asset ratio of nearly 80%, prompting analysts to suggest the debt was approaching its limit. IQVIA’s GAAP earnings per share and adjusted EPS missed analyst estimates in the second quarter of 2025. A July 2025 report noted that while IQVIA’s Technology and Analytics Solutions segment performed well, the larger Research & Development Solutions segment experienced much slower growth. Analyst commentary suggested that competitors with more integrated ecosystems could create long-term challenges. Macroeconomic uncertainty and U.S. government actions affecting the biopharmaceutical industry have led to drug development projects being put on hold. This resulted in IQVIA’s book-to-bill ratio declining to its lowest level since 2019. Analyst coverage in July 2025 suggested that increased competition, particularly from players with more innovative and integrated ecosystems, pose a challenge to IQVIA’s long-term market position. Please vote yes: Independent Board Chairman – Proposal 5

DISCLAIMER: By including a shareholder resolution or management proposal in this database, neither the PRI nor the sponsor of the resolution or proposal is seeking authority to act as proxy for any shareholder; shareholders should vote their proxies in accordance with their own policies and requirements.

Any voting recommendations set forth in the descriptions of the resolutions and management proposals included in this database are made by the sponsors of those resolutions and proposals, and do not represent the views of the PRI.

Information on the shareholder resolutions, management proposals and votes in this database have been obtained from sources that are believed to be reliable, but the PRI does not represent that it is accurate, complete, or up-to-date, including information relating to resolutions and management proposals, other signatories’ vote pre-declarations (including voting rationales), or the current status of a resolution or proposal. You should consult companies’ proxy statements for complete information on all matters to be voted on at a meeting.